Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries
Gevorg Tamamyan/LinkedIn
Jan 4, 2026, 14:51

First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries

Gevorg Tamamyan, Editor-in-Chief and Co-Founder of OncoDaily, shared on LinkedIn:

“Here we present the first results from the BPDCN International Registry, established by the Immune Oncology Research Institute.

Title: Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program

Authors: Astghik Voskanyan, Maria Badikyan, Marina Konopleva, Alvaro Alencar, Arusyak Ivanyan, Carolyn Owen, Consolato M Sergi, Ching-Tien Peng, Dickran Kazandjian, Justin Taylor, Funda Tekkesin, Hasanein Ghali, Karen Bedirian, Maria Paola Martelli, Enrico Attardi, Maria Teresa Voso, Mariam Abramashvili, Mazin Faisal Al-Jadiry, Michalis Michael, Min-Yu Su, Nare Martirosyan, Nerses Ghahramanyan, Nino Totogashvili, Pavel P Kotoucek, Rejin Kebudi, Robin Ohannessian, Ruzanna Papyan, Shushan Hovsepyan, Salma Elashwah, Sameer Bakhshi, Samvel Bardakhchyan, Samvel Danelyan, Shaimaa El-Ashwah, Tezer Kutluk, Deniz Tuğcu, Ahmad Alhuraiji, Vassilios Lazaris, Gevorg Tamamyan, Naveen Pemmaraju

First Results from the International BPDCN Registry: Data from 36 Patients Across 12 Countries

BPDCN is a rare and aggressive hematologic malignancy. In this initial report, we captured data from 36 patients across 12 countries—a meaningful start for a disease where every case matters.

Since then, the registry has more than doubled in size. New centers and additional countries have joined this growing international effort. Yet for rare malignancies like BPDCN, more is not optional—it is essential. Progress depends on collecting the most comprehensive, global dataset possible.

If you are a hematologist–oncologist, pediatric or adult, anywhere in the world, and you have managed or are managing a BPDCN case, we invite you to join this collaboration.

For rare diseases, collaboration is not an advantage. It is the only way forward.”

Read more from Gevorg Tamamyan on Hemostasis Today.

Astghik Voskanyan Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Gevorg Tamamyan Headlines Health hematologic malignancy Hemostasis Hemostasis Today Immune Oncology Research Institute Maria Badikyan Marina Konopleva Medicine Naveen Pemmaraju thrombosis
NewsFeed